These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 15731142)
1. FDA advisers warn: COX 2 inhibitors increase risk of heart attack and stroke. Lenzer J BMJ; 2005 Feb; 330(7489):440. PubMed ID: 15731142 [No Abstract] [Full Text] [Related]
2. Market withdrawal of Vioxx: is it time to rethink the use of COX-2 inhibitors? Ortiz E J Manag Care Pharm; 2004; 10(6):551-4. PubMed ID: 15548128 [TBL] [Abstract][Full Text] [Related]
3. MI risk prompts rofecoxib withdrawal. Thompson CA Am J Health Syst Pharm; 2004 Nov; 61(21):2234-6, 2238. PubMed ID: 15552625 [No Abstract] [Full Text] [Related]
4. [New study of selective COX-2 inhibitors. Protecting the stomach while risking the heart? (interview by Dr. Beate Schumacher)]. Zeidler H MMW Fortschr Med; 2001 Sep; 143(35-36):14. PubMed ID: 11584521 [No Abstract] [Full Text] [Related]
5. Why do COX-2 inhibitors increase risk of cardiovascular events? Frankish H Lancet; 2002 Apr; 359(9315):1410. PubMed ID: 11978344 [No Abstract] [Full Text] [Related]
6. Lessons learned after the withdrawal of rofecoxib. Giaquinta D Manag Care Interface; 2004 Nov; 17(11):25-6, 46. PubMed ID: 15573801 [No Abstract] [Full Text] [Related]
7. COX-2 inhibitors--lessons in drug safety. Psaty BM; Furberg CD N Engl J Med; 2005 Mar; 352(11):1133-5. PubMed ID: 15713946 [No Abstract] [Full Text] [Related]
8. Arthritis. Should you be taking a COX-2 inhibitor? Harv Health Lett; 2001 Nov; 27(1):1-3. PubMed ID: 11724695 [No Abstract] [Full Text] [Related]
9. Researchers plan to continue to study COX-2 inhibitors in cancer treatment and prevention. Vanchieri C J Natl Cancer Inst; 2005 Apr; 97(8):552-3. PubMed ID: 15840872 [No Abstract] [Full Text] [Related]
10. The Vioxx debacle. Fielder JH IEEE Eng Med Biol Mag; 2005; 24(2):106-9. PubMed ID: 15825852 [No Abstract] [Full Text] [Related]
11. Cardiovascular complications of COX2 selective inhibitors cause considerable concern. Hedner T; Himmelmann A Blood Press; 2004; 13(5):260-1. PubMed ID: 15545147 [No Abstract] [Full Text] [Related]
12. COX-2 inhibitor use after Vioxx: careful balance or end of the rope? Fendrick AM Am J Manag Care; 2004 Nov; 10(11 Pt 1):740-1. PubMed ID: 15623263 [No Abstract] [Full Text] [Related]
13. Failing the public health--rofecoxib, Merck, and the FDA. Topol EJ N Engl J Med; 2004 Oct; 351(17):1707-9. PubMed ID: 15470193 [No Abstract] [Full Text] [Related]
14. COX 2 inhibitors may increase risk of heart attack. Gottlieb S BMJ; 2001 Sep; 323(7311):471. PubMed ID: 11532833 [No Abstract] [Full Text] [Related]
15. COX-2 inhibitors--a lesson in unexpected problems. Drazen JM N Engl J Med; 2005 Mar; 352(11):1131-2. PubMed ID: 15713947 [No Abstract] [Full Text] [Related]
16. Differences between COX-2-specific inhibitors: clinical and economic implications. Sonnenblick EH Am J Manag Care; 2002 Oct; 8(15 Suppl):S428-30. PubMed ID: 12416792 [No Abstract] [Full Text] [Related]
17. COX-2 inhibitors: cancer prevention or cardiovascular risk? Senior K Lancet Oncol; 2005 Feb; 6(2):68. PubMed ID: 15704289 [No Abstract] [Full Text] [Related]
18. Coxibs and cardiovascular disease. Fitzgerald GA N Engl J Med; 2004 Oct; 351(17):1709-11. PubMed ID: 15470192 [No Abstract] [Full Text] [Related]
19. The risk for myocardial infarction with cyclooxygenase-2 inhibitors. Kim JA; Choi YS; Yoon D; Cho KH Ann Intern Med; 2005 Oct; 143(8):615-6; author reply 617-8. PubMed ID: 16230734 [No Abstract] [Full Text] [Related]